During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.
Related to this article
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.
During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
2
FDA Approves Pixclara, First FET-PET Agent for Glioma Imaging
3
After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data
4
FDA Clears Robotic System for Endoscopic Procedures in the Colon
5